Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Álvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is a common chronic immune-media...
Saved in:
Main Authors: | Machado Á, Torres T |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/0024f89d204e4d6f81ccd0f66c542e61 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022) -
Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
by: Annunziata Dattola, et al.
Published: (2021) -
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018) -
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
by: Reddy V, et al.
Published: (2020)